Silo Pharma Inc（SILO）财务数据SILOSilo Pharma Inc

Evaluating the bottom line, Silo Pharma Inc maintains a gross margin of -14.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13999.83%, while the net margin is -13757.61%. These profitability ratios, combined with a Return on Equity (ROE) of -91.23%, provide a clear picture of how effectively SILO converts its operational activities into shareholder value.

In the context of the broader market, SILO competes directly with industry leaders such as SBFM and SLXN. With a market capitalization of $2.93M, it holds a leading position in the sector. When comparing efficiency, SILO's gross margin of -14.77% stands against SBFM's 25.35% and SLXN's N/A. Such benchmarking helps identify whether Silo Pharma Inc is trading at a premium or discount relative to its financial performance.

Silo Pharma has a gross margin of 91.90%, which is strong, but it has reported consistent net losses, with a net income of -1,647,117 USD in Q1 2026.